A Study of BGM0504 in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 553 participants.
Also called NCT06716216
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 553 participants
- Registry
-
NCT06716216
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06716216. Randomized; no masking; primary purpose treatment. Start 2025-01-13 (actual); primary completion 2026-08-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of BGM0504 in Participants With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- Drug: 5 mg BGM0504 Administered SC
- Intervention (Drug)
- Drug:10 mg BGM0504 Administered SC
- Intervention (Drug)
- Drug: Semaglutide Administered SC
- Lead sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Collaborator
- BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
Record details
- Record id
cardio:ct-nct06716216- Content hash
a7678ea5e1562fe7a0f1d4964734dd5144b6a3e045fac3bcdd8aecaa2f2b4720